HEALTH POLICY REVIEW: REGIONAL REFORMS IN HOSPITALS, MEDICAL PERSONNEL SYSTEM, AND MODE OF PAYMENT IN CHINA

A285

VA L U E I N H E A LT H 1 9 ( 2 0 1 6 ) A 1 - A 3 1 8

adherence changes, new indications, and epidemiological changes into determining cost-effectiveness.  Conclusions: This review documents a variety of approaches for design of CEAs with variations in study design approaches that effect cost and effectiveness. Few studies incorporated dynamic effects into the CEA.

better protected than before, while benefits on urban employees are observed to be less reformed. Further quantitative studies on effects of latest health care policies call for more public data.

PHP159 MEASURING SATISFACTION LEVEL WITH HEALTH INSURANCE

PHP162 OPPORTUNITIES FOR THE ISPOR STUDENT NETWORK TO COMPLEMENT THE CURRENT ACADEMIC CURRICULUM

Abd Rabuh A , Izham M Qatar University, Doha, Qatar

1University

.

.

.

Objectives: In an attempt to analyze the trend of increasing per capita spending on healthcare expenditure among employees and their families, we tried to measure the characteristics that could contribute to that. We set the spending as a function of satisfaction; whereas, knowing the characteristics of the insured people will help determine their satisfaction and, in turn, their spending pattern. In our hypothesis we tested the effect of demographics (i.e gender, ethnicity, age and education level) on satisfaction level.  Methods: After conducting exploratory interviews with administrators from both of the insurance company and the client, we realized that there has been complaints on several aspects of the medical claiming process. Initially, we classified these complaints into four constructs: process-design, financial aspects, prescriptions and service providers. In order to have an unbiased data collection tool, an online survey questionnaire was sent to QU community of 2,044 staff and faculty and 373 responses were collected.  Results: The distribution of the satisfaction responses showed normality using a descriptive exploratory test. On a 4-scale ranging from 1= ”Very Dissatisfied” to 4= ”very satisfied”, the overall average of satisfaction recorded an average of 2.87 ± 0.64 showing a tendency toward satisfaction. The process design construct scored the highest with a 3.11 average. Conversely, lowest satisfaction was scored in the financial aspects construct where average of 2.59 and highest standard deviation (0.84) were scored.  Conclusions: T-test for gender and ethnicity characteristics and Oneway ANOVA test for age and education confirmed that there is no significant attribution to satisfaction by the aforementioned demographics. The study should apply the same tests on each construct individually to get more specific insights. PHP160 WHAT CAN HEALTH ECONOMISTS LEARN FROM VW : WOULD NEW VALUES FOR EQ-5D MEAN A PRODUCT RECALL FOR PAST ICERS? Marti J 1, Kind P 2 1Imperial College, London, UK, 2HSE University, St Petersburg, Russia .

.

Objectives: Guidance for HTA in several health jurisdictions mandates the use of EQ-5D in the measurement of health benefits. In the UK a standard scoring system for EQ-5D-3L was established in a 1993 survey using a subset of 45/243 directly observed states. Significant advances in data analysis and modelling over the past 20 years might now yield a different scoring system. In this paper, we assess the circumstances under which modifications of the valuation set for EQ-5D-3L would produce changes in marginal QALYs and whether such changes would compromise the status of existing cost-effectiveness decisions.  Methods: The 1993 scoring system was compared with a number of alternatively derived value sets that explored the influence of parameter and structural uncertainty. The influence of these methodological factors on the distribution of the (243x242)/2 pairwise differences in health state utilities was tested using a range of values for incremental cost and cost-effectiveness threshold to establish the conditions under which past cost-effectiveness decisions might need to be revised.  Results: Our analysis shows important variation in the ICERs obtained using different value sets. In particular, when the relevant incremental QALY corresponds to a health improvement where one dimension changes from level 3 (“extreme” problems) to level 2 (“moderate” problems), ICERs are particularly sensitive to the inclusion of the “N3” constant in the model. For a range of baseline QALYs and health improvements, the decisions that have been made based on ICERs generated with the 1993 MVH value set may have been drastically different had another specification been used.  Conclusions: The specification of the model used to estimate values for EQ-5D-3L health states has a pronounced impact on the scoring system that can compromise the legitimacy of economic evaluation of interventions targeting severe ill-health. This study has implications for the transitional use of the 5L and 3L versions of EQ-5D. PHP161 HEALTH POLICY REVIEW: REGIONAL REFORMS IN HOSPITALS, MEDICAL PERSONNEL SYSTEM, AND MODE OF PAYMENT IN CHINA Zhang Y 1, Jiang S 2, Long J 3, DONG Y 3 1Columbia University, Cliffside Park, NJ, USA, 2University of British Columbia, Vancouver, BC, Canada, 3Zhejiang Women’s Hospital, Hangzhou, China .

.

.

Gaitonde P 1, LyttleNguessan C J 2, Cannon-Dang E 3, Shah A B 4, Oehrlein E M 5, Khan Z M 6 of Maryland, Baltimore, MD, USA, 2Florida A&M University, Tallahasse, FL, USA, 3Thomas Jefferson University, Philadelphia, PA, USA, 4University of Arkansas for Medical Sciences, Little Rock, AR, USA, 5University of Maryland School of Pharmacy, Baltimore, MD, USA, 6Celgene Corporation, Summit, NJ, USA

.

Objectives: The vast increase of the coverage of medical insurance from 89.25% to 95% during 2009 and 2014 in China has been evaluated as an initial reform in realizing universal health care. In order to understand how the latest health care policies leverage the utilization of medical services, this paper reviews Chinese regional health policies from 2009 to 2015, and critiques on their effects in implementations.  Methods: This study was derived from 76 major policy documents, including reforms in public and private hospitals, medical personnel system, and mode of payment, originating in Ministry of Human Resources and Social Security, Ministry of Finance, Ministry of Health, and National Development and Reform Commission in China.  Results: Overall, the latest regional health policies, especially in municipalities directly under the Central Government and economically more developed provinces, provide more accessibilities to community general physicians, higher reimbursement rates in critical illness insurance programs, and more incentives to private funded hospitals. Additionally, it makes a breakthrough in terms of the prevalence of public hospitals and local medical institutions, and the standardization of financial inputs and distributions in economically less developed provinces.  Conclusions: The current Chinese regional health care policies are originated with large freedoms according to local development in health systems. Medical insurance participants in rural areas and unemployed urban residents are

.

.

.

.

.

.

.

.

.

Objectives: The curricular needs of graduate students studying pharmacoeconomics and outcomes research (HEOR) are very broad with topics from health policy and economics to epidemiologic methods. Given the diversity of topics areas, individual academic HEOR departments may have difficulty introducing students to each of these topics. To examine topic areas where the ISPOR Student Network (SN) may complement existing academic curriculum through webinars and trainings, the SN undertook a survey of student members to identify research concepts important for HEOR, but not necessarily covered by departmental curriculum.  Methods: The survey was fielded among all ISPOR SN members in November 2015. It contained questions aimed at evaluating familiarity with topics under three broad domains: CER/Pharmacoeconomic concepts, methodological considerations, and resources. Responses were in form of Likert scale and/or were open ended. We qualitatively analyzed the frequencies and have reported the topics where ≥  50% were “not familiar” or had “little familiarity”.  Results: Survey participants (n= 91) were primarily based in North America (53.8%) and enrolled in master’s or PhD programs. Respondents were unfamiliar with: cost regression analysis (56.04%), discrete event simulation modelling (67.03%), all types of uncertainty analyses (~ 63%), and CEAC/ CEAF/value of information (63.3%). Within health policy topics with little familiarity include: risk sharing agreements (70.3%), and regulatory processes for medical devices 62.6%). We observed that only 55% of the respondents were familiar with SAS and STATA. Courses at school are the primary source of information for students.  Conclusions: The concepts of least familiarity among the student researchers were uncertainty analysis and health policy-related issues. The results of this survey have highlighted some of the specialized topics on outcomes research, which will inform subject matter for ISPOR SN-led educational programming and provide suggestions for supplementary discussions in the courses taught at the Universities. PHP163 NEW TOOLS FOR NEW CHALLENGES: IMPROVING THE UTILITY OF COMPARATIVE EFFECTIVENESS RESEARCH IN DECISION MAKING Pickering M K 1, Perfetto E M 2, Zaghab R W 1, Graff J S 3, Saha S 4 1University of Maryland, School of Pharmacy, Baltimore, MD, USA, 2National Health Council, Washington, DC, USA, 3National Pharmaceutical Council, Washington, DC, USA, 4Academy of Managed Care Pharmacy, Alexandria, VA, USA .

.

.

.

.

.

.

.

.

Objectives: Little guidance is available on how to evaluate and use CER studies, creating risk for data misinterpretation and under-utilization of critical information to inform healthcare decision-makers. The aim of this study was to determine the effectiveness of a CER Certificate Program (CCP), largely derived from task-force reports and online CER Collaborative tools, on the learners’ use of evidence from CER studies. This study also assessed the CCP’s performance compared to previous data from its initial cohort.  Methods: One-hundred and seven healthcare professionals participated in a 19-hour, ACPE-approved CCP. Five self-paced, online multi-media modules utilized the CER Collaborative online tools and resources for: prospective and retrospective observational studies, indirect treatment comparisons, models, and synthesizing results from various study designs. A live workshop engaged learners with case presentations and peer critique. Upon completion, learners assessed their ability to evaluate and use evidence from CER studies in day-to-day decisionmaking using a Likert scale (1= strongly disagree, 5= strongly agree). Follow-up evaluations occurred at 2 and 6 months.  Results: Of the 107 graduates, 103 completed post-program evaluation. At completion, learners reported increased confidence (mean= 4.3) and a 26-56% improvement in their capabilities to evaluate various CER studies. Additionally, 81% indicated an expected increase the use of evidence from CER studies in at least 1-2 problem decisions per month. Results were consistent with a previous initial cohort (N= 18). At follow-up, 56% of respondents indicated they had incorporated findings from CER studies in at least two CER-related decisions at 2 months and at least six decisions at 6 months.  Conclusions: As new or unfamiliar CER study designs become available, there will be an increasing need to understand how to assess the relevance and credibility of CER studies to inform decision-making. The CCP was found to consistently improve healthcare decisionmakers’ self-reported abilities in assessing and applying CER in their work settings. PHP164 FDA PATIENT-REPORTED OUTCOME LABELING OF NOVEL THERAPIES (2011-2015) Gnanasakthy A , Mordin M , Haydysch E , DeMuro C RTI Health Solutions, Research Triangle Park, NC, USA .

.

.

.

Objectives: For the period covering 2006 and 2010, 24.1% of newly approved drugs by the FDA had at least one PRO related labeling (Gnanasakthy et. al. (2012)). This study aimed to assess PRO related labeling of new products covering the period between 2011 and 2015 to examine differences compared to the previous assessment.  Methods: Using the Drugs@FDA database, new drugs approved by FDA between January 2011 and December 2015 were identified. For all identified drug products, medical review sections from publicly available drug approval packages (DAPs) were reviewed. Product labeling (indication, clinical trials sections) were reviewed to determine PRO related labeling and the corresponding endpoint status.  Results: Of the 182 new drugs identified, 30 (16.5%) were granted PRO claims. The vast majority of labeling related to primary endpoints (76.7%), and were based